Physician profile
Kwok Li
NPI 1487641353
$1,677.83
in general payments reported to CMS, 2019-2025
20 companies · $344 in 2025
The $344 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $229 · 2020: $212 · 2021: $179 · 2022: $304 · 2023: $178 · 2024: $231 · 2025: $344.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $744 · Gift: $10.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $743.55 |
| Gift | $10.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $282.57 | 2019-2025 | Clareon, Rocklatan |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $241.01 | 2019-2021 | |
| Rxsight INC | $168.49 | 2025 | Rxsight Light Delivery Device (Ldd), Rxsight Injector Handpiece, Rxsight Injector Cartridge |
| Bausch & Lomb Americas INC. | $160.26 | 2022-2023 | Miebo, Vyzulta, Zylet |
| Johnson & Johnson Surgical Vision, INC. | $129.24 | 2022-2024 | Tecnis Iol, Veritas Vision System |
| Vertex Pharmaceuticals Incorporated | $109.39 | 2025 | |
| Tarsus Pharmaceuticals, INC. | $91.90 | 2024-2025 | Xdemvy |
| Allergan, INC. | $66.16 | 2019-2020 | |
| Sun Pharmaceutical Industries INC. | $65.03 | 2019-2021 | |
| Dompe US, INC. | $61.52 | 2019-2024 | Oxervate |
| Novartis Pharmaceuticals Corporation | $59.76 | 2019-2022 | |
| Oyster Point Pharma, INC. | $57.16 | 2022-2023 | Tyrvaya |
| Ocular Therapeutix, INC. | $38.06 | 2020-2021 | |
| Abbvie INC. | $28.79 | 2022 | |
| Sight Sciences, INC. | $23.51 | 2022 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kala Pharmaceuticals, INC. | $22.06 | 2022 | |
| Merz North America, INC. | $21.82 | 2019 | |
| Shire North American Group INC | $20.78 | 2019 | |
| Glaukos Corporation | $20.32 | 2021 | |
| Purelife, LLC | $10.00 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kwok Li listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.